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Abstract
Background: The prognosis of patients with incurable head and neck cancer (HNC) is a relevant topic. The mean
survival of these patients is 5 months but may vary from weeks to more than 3 years. Discussing the prognosis
early in the disease trajectory enables patients to make well-considered end-of-life choices, and contributes to a
better quality of life and death. However, physicians often are reluctant to discuss prognosis, partly because of the
concern to be inaccurate. This study investigated the accuracy of physicians’ clinical prediction of survival of
palliative HNC patients.
Methods: This study was part of a prospective cohort study in a tertiary cancer center. Patients with incurable HNC
diagnosed between 2008 and 2011 (n = 191), and their treating physician were included. Analyses were conducted
between July 2018 and February 2019. Patients’ survival was clinically predicted by their physician ≤3 weeks after
disclosure of the palliative diagnosis. The clinical prediction of survival in weeks (CPS) was based on physicians’
clinical assessment of the patient during the outpatient visits. More than 25% difference between the actual survival
(AS) and the CPS was regarded as a prediction error. In addition, when the difference between the AS and CPS was
2 weeks or less, this was always considered as correct.
Results: In 59% (n = 112) of cases survival was overestimated. These patients lived shorter than predicted by their
physician (median AS 6 weeks, median CPS 20 weeks). In 18% (n = 35) of the cases survival was correctly predicted.
The remaining 23% was underestimated (median AS 35 weeks, median CPS 20 weeks). Besides the differences in AS
and CPS, no other significant differences were found between the three groups. There was worse accuracy when
predicting survival closer to death: out of the 66 patients who survived 6 weeks or shorter, survival was correctly
predicted in only eight (12%).
Conclusion: Physicians tend to overestimate the survival of palliative HNC patients. This optimism can result in
suboptimal use of palliative and end-of-life care. The future development of a prognostic model that provides more
accurate estimates, could help physicians with personalized prognostic counseling.
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Background
HNC patients in general have a poor prognosis. The
five-year survival rate varies between 30 and 70%,
depending on the stage and location of the tumor [1].
Consequently, HNC treating physicians are regularly
confronted with patients entering the palliative phase.
The survival of patients with incurable HNC is short,
with a mean of 5 months which can range from days to
more than 3 years [2]. In our institute, we define the pal-
liative phase as beginning at the moment of diagnosis of
an incurable head and neck tumor or when the patient
declines curative treatment [2, 3]. A head and neck
tumor can be incurable for several reasons: inoperability
plus no other curative treatment options, distant metas-
tasis, the presence of severe comorbidity, and/or poor
performance status of the patient.
Adequate counseling in the palliative phase requires
an insight of what and when can be expected during the
course of disease. HNC in this phase can cause specific
end-of-life issues because of its local anatomy and the
consequences of treatment. Examples are airway compli-
cations, communication difficulties, dysphagia, facial dis-
figurement, neuropathic pain, and psychosocial
complaints [4, 5]. Given the short length of the palliative
phase, discussing prognosis early in the disease trajectory
enables patients to make well-considered end-of-life
choices which could contribute to a better quality of life
(QoL), and quality of death (QoD) [6]. Previous research
has shown that patients, caregivers, and physicians have
different views on a “good death” [7, 8]. Although there
is no clear definition of the concept, there are some re-
current themes derived from qualitative research among
terminal patients with and without cancer. A recently
published systematic review that focused on patients’
perspectives on a “good death” identified the following
core elements: control of pain and symptoms, clear deci-
sion making, feeling of closure, being seen and perceived
as a person, preparation for death, and being still able to
give something to others [8]. A “good death” is based on
individual preferences and shaped by culture, religion,
age, disease, financial status and life circumstances [8].
Talking about death and asking patients in the pallia-
tive phase what they consider to be a “good death” could
also help to identify goals for end-of-life care [9]. Earlier
studies showed that patients who have discussed end-of-
life care with their physician, are less likely to receive
burdensome care, like chemotherapy, and more likely to
receive hospice care [10, 11]. Adequate timing of coun-
seling is crucial and therefore a reliable prediction of the
remaining life-span can be valuable information for
patients. Furthermore, various studies have shown incur-
able patients’ desire for detailed prognostic information
[12–14]. This allows them to prepare themselves and
their families for what’s coming, and assist in their end-
of-life decisions [13]. Consequently, end-of-life discussion
are an important part of oncologists’ work. However,
physicians often feel uncomfortable and reluctant to
discuss prognosis in the palliative phase, partly because of
the concern to potentially being proved inaccurate [15]. In
addition, doctors’ natural impulse is to treat, while a
palliative patients desire may be different after realistic
prognostic disclosure.
Are doctors’ worries about inaccurate estimations of
survival legitimate? Previous studies on prognostic
accuracy in palliative care are heterogeneous and none
of these studies focused on HNC specifically [16, 17].
This study set out to examine the accuracy of physicians
estimations of survival of palliative HNC patients.
Methods
Study design
Data were collected during a prospective cohort study,
approved by our medical ethical committee [MEC
2008–133]. During this study palliative patients with
histologically proven squamous cell carcinoma of the
head and neck were eligible for inclusion. Patients’
palliative diagnosis was discussed in our tumor board.
Subsequently, the patients were informed the next week.
Hereafter, patients’ survival was predicted by their treat-
ing physician by reporting how long they thought the
patient would live (open text field). This clinical predic-
tion of survival (CPS) was based on physicians’ clinical
assessment of the patient during the outpatient visits.
These estimations were physicians’ best guesses about
the remaining life-span of these patients (physician-
recalled). Information about survival was only communi-
cated to patients on their request. Analyses were con-
ducted between July 2018 and February 2019.
Eligibility criteria
Figure 1 shows a flowchart of patient inclusion. Palliative
patients with histologically proven squamous cell carcin-
oma of the head and neck who were seen in the Erasmus
MC Rotterdam Cancer Institute from October 2008
until October 2011 were eligible for inclusion (n = 318).
Subsequently, in 269 patients survival was predicted by
their physician. Of the 269 patients, 27 received euthan-
asia and were excluded. Patients given palliative sedation
(n = 88) were not excluded, as the goal of palliative
sedation is to relieve suffering, and not to shorten
patients life [18]. Survival was predicted by their phys-
ician shortly before or after the outpatient visit in which
the palliative diagnosis was communicated. In 50 cases
survival was predicted more than 3 weeks after this out-
patient visit. To limit recall bias of the clinical assess-
ment, these 50 patients were excluded. In the remaining
group one patient was still alive at the end of follow-up
and was also excluded. The clinical prediction of survival
Hoesseini et al. BMC Palliative Care          (2020) 19:176 Page 2 of 10
(CPS) in the remaining 191 patients was analyzed.
Patient and tumor data were collected from the electro-
nical patient file. The majority of predictions was made
by eight head and neck surgeons (92.1%, n = 176),
followed by two radiotherapists (7.9%, n = 15), with
varying levels of practice experience.
Definitions
 Palliative phase was defined as beginning at the
moment of diagnosis of an incurable head and neck
tumor or when the patient declines curative
treatment (palliative diagnosis). A head and neck
tumor can be incurable for several reasons:
inoperability plus no other curative treatment
options, distant metastasis, the presence of severe
comorbidity, and/or poor performance status of the
patient.
 Actual survival (AS) was defined as the period in
weeks between the consultation in which the
palliative diagnosis was communicated and the
actual date of death.
 Clinical prediction of survival (CPS) was defined as
the period in weeks between the consultation in
which the palliative diagnosis was communicated
and the predicted date of death.
 The survival difference (SD) was defined as the time
in weeks between the AS and the CPS.
 The prediction error was defined as > 25% survival
difference between the AS and the CPS.
Institutional routine
In our institution, patients with head and neck cancer
are evaluated by the head and neck surgeons and the ra-
diotherapists. After diagnostics, patients are discussed in
our multidisciplinary tumor board. In this weekly board
meeting, medical oncologists, head and neck surgeons,
radiotherapists, radiologists, geriatricians, and physician
assistants are present to discuss all patients with a HNC
diagnosis, both curative and palliative. After the board
meeting, the responsible physician discusses the boards’
recommendations with the patient during a patient en-
counter as soon as possible. When either the board or
the patient decide to pursue a palliative trajectory, pa-
tients are referred to our Expert Center for Palliative
Care. In 2005 we have set up this Center for patients
with HNC and their families or significant others, aiming
to improve the quality of life in the palliative phase [19].
The Expert Center team consist of: a dedicated head and
neck cancer surgeon acting as a clear contact person for
patients, specialist nurses, psychologists, speech thera-
pists, a pain team including anesthesiologists, a dietician,
social workers, and representatives of the religious pro-
fession. The specialized nurses provide information and
psychosocial support to patients and relatives, handle
pain management, and screen psychosocial needs and
Fig. 1 Flowchart summarizing inclusion and exclusion criteria. CPS = Clinical prediction of survival
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other relevant data for effective allocation of specialized
care [19]. They also contact general practitioners (GP),
as GP’s rarely see HNC cases in their daily practices.
These nurses play a crucial role by ensuring more effi-
cient and effective communication between physician,
patient, and other caregivers [19]. Since 2016, patients
are also monitored using a validated questionnaire:
EORTC QLQ-C15-PAL [20], which measures quality of
life and functioning in the palliative phase. As patients
may be too fragile to visit the hospital, this is often done
by telephone.
Clinical prediction of survival groups
We defined three prediction groups:
1) Correct prediction: ≤ 25% difference between the AS
and the CPS. In addition, when the difference
between the AS and the CPS was 2 weeks or less,
this was always considered as correct.
2) Underestimation: the AS was > 25% longer than the
CPS, i.e. patients lived longer than predicted.
3) Overestimation: the AS was > 25% shorter than the
CPS, i.e. patients lived shorter than predicted.
Statistical analysis
Statistical analysis was done using Statistical Package for
the Social Sciences (SPSS) statistics version 25. All tests
were 2 sided with P < 0.05 as the limit of statistical sig-
nificance. Tests used for continuous variables were the
Independent-Samples Mann-Whitney U test, and the
Independent-Samples Kruskal-Wallis test. The Pearson
χ2 test was used for categorical variables. Overall survival
function was analyzed using the Kaplan-Meier method.




Patient characteristics of both the included and excluded
group are shown in Table 1. There were no missing
data. No significant differences were found between the
excluded and included group. In total 191 (60%) out of
318 patients were included. The patient who was still
alive at follow-up had an inoperable T4N0M0 squamous
cell carcinoma of the maxillary sinus and was treated
with palliative radiotherapy consisting of 16 fractions of
3.13 Gy, with a total dose of 50.08 Gy.
Clinical prediction of survival
Figure 2 shows a scatter plot of the CPS versus the AS.
Each point represents a patient. Figure 3 shows the over-
all survival function of the AS and CPS of all patients
(p = 0.124). Characteristics of the different survival predic-
tion groups are shown in Table 2. In only 18% (n = 35) of
cases survival was correctly predicted, while 59% (n = 112)
of patients lived shorter than predicted (overestimation).
The remaining 23% lived longer than predicted (underes-
timated). Variables with missing data were: n = 4 marital
status (2.1%), n = 4 smoking (2.1%), n = 5 alcohol (2.6%),
n = 26 no. alcohol units / day (13.6%), and n = 37 Body
Mass Index (BMI) (19.4%). The AS and CPS differed sig-
nificantly between groups. No other significant differences
were found between groups. Out of the 66 patients who
survived 6 weeks or shorter, survival was correctly pre-
dicted in only eight (12%) patients and overestimated in
the remaining 58 (88%) patients.
Discussion
This study set out to examine the accuracy of physicians’
clinical prediction of survival in palliative HNC. Survival
predictions were accurate in less than one out of five
palliative HNC patients (18%), while 59% of the predic-
tions were overoptimistic, meaning that patients lived
shorter than predicted by their physician. This overesti-
mated group had the worst actual survival with a median
of 6 weeks. Furthermore, we found, in agreement with
earlier research, worse accuracy when predicting survival
closer to death [21]: out of the 66 patients who survived
6 weeks or shorter, survival was correctly predicted in
only 12%.
Our results were comparable with previous research
among other cancer types that also showed physicians’
tendency to overestimate [16, 17, 21–24]. Several factors
may be associated with a lower prognostic accuracy.
First, the level of physicians’ knowledge on mean
survival rates in palliative HNC patients could have
caused some optimism in their clinical prediction. This
knowledge is partly based on a previously reported mean
survival rate of 5 months [2], while the current study
shows a median survival of only 3 months. This former
reported more favorable survival could be due to the
inclusion of patients with skin cancer (5.7%), histology
other than squamous cell carcinoma (10.3%), and includ-
ing less patients with severe comorbidity, defined by an
Adult Comorbidity Evaluation 27 (ACE-27) score of 3
(9.5% versus 18.6% in the current study). Another factor
that could be associated with lower prognostic accuracy
is the duration of the doctor-patient relationship: the
longer the doctor knows the patient, the lower the
prognostic accuracy [22]. Doctors are trained to act,
solve problems, and treat patients. Being optimistic and
overestimating survival could therefore be a strategy to
maintain hope [25]. Although this strategy seems plaus-
ible, evidence suggests that hope is maintained by the
truth [26–28]. In an advanced cancer population, pa-
tients who were given a poor prognosis in terms of
survival and QoL, low chance of response to treatment,
and no chance of cure remained hopeful about their
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future [26–28]. Not only do physicians tend to overesti-
mate survival, patients are also prone to do so [29, 30].
This could be due to misinterpretation or lack of
information, as patients often do not receive prognostic
information from their physicians [31–34]. Patients’
denial affects misunderstanding the prognosis and goals
of treatment [35, 36]. Although patients often do not re-
ceive prognostic information, they generally have high
levels of information need about life expectancy and they
want at least some discussion of this topic at the time of
diagnosis or shortly after [37]. While some patients seek
qualitative information about the prognosis, for example:
is the illness curable?, others prefer quantitative informa-
tion like survival rates or other statistics [14, 36, 38].
Curatively treated HNC patients that participated in our
focus group research had a stronger preference for
quantitative prognostic information in the hypothetical
case of cancer recurrence and a poor prognosis [36]. Be-
sides meeting patients’ information needs, providing
prognostic information in the palliative phase can affect
Table 1 Patient characteristics
Included Excluded P Value
No. of patients 191 127 –
Median age, years (Q1 – Q3) 64.0 (57.0–76.0) 64.0 (55.0–69.0) 0.142
Age range, years 23–100 42–91 –
Sex
Men 138 (72.3%) 96 (75.6%) 0.508
Women 53 (27.7%) 31 (24.4%)
Tumor localization
Lip 0 1 (0.8%)
Oral cavity 54 (28.3%) 35 (27.6%)
Oropharynx 54 (28.3%) 40 (31.5%)
Nasopharynx 4 (2.1%) 5 (3.9%) –
Hypopharynx 26 (13.6%) 15 (11.8%)
Larynx 33 (17.3%) 17 (13.4%)
Nasal cavity 3 (1.6%) 5 (3.9%)
Maxillary sinus 5 (2.6%) 2 (1.6%)
Salivary gland 2 (1.0%) 0
Unknown primary 10 (5.2%) 7 (5.5%)
Tumor stage
I - III 15 (7.9%) 16 (12.5%)
IVa 55 (28.8%) 41 (32.3%) –
IVb 31 (16.2%) 15 (11.8%)
IVc 90 (47.1%) 55 (43.3%)
ACE-27
0 46 (24.1%) 31 (24.4%)
1 61 (31.9%) 31 (24.4%) 0.401
2 53 (27.7%) 37 (29.1%)
3 31 (16.2%) 28 (22.0%)
Cause incurable disease
No curative treatment possible 172 (90.1%) 105 (82.7%) 0.055
Patients’ choice 19 (9.9%) 22 (17.3%)
Palliative sedation 68 (35.6%) 32 (25.2%) 0.050
Euthanasia 0 27 (21.3%) –
Carotid blowout syndrome 9 (4.7%) 5 (3.9%) –
Suicide 0 1 (0.8%) –
Median survival, weeks (95% CI) 12.0 (9.3–14.7) 12.0 (7.7–16.3) 0.753
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patients’ end-of-life choices. An accurate estimation of
survival makes it possible to communicate a more realistic
indication of the end-of-life with the patient. Consequently,
physicians and their palliative team can optimize palliative
care planning. This may also have an impact on decisions
about palliative treatment or involvement in clinical trials
[10, 11, 29]. Multiple studies have shown that with pallia-
tive or hospice care survival is not reduced, but equal or
even prolonged [26, 39, 40]. Temel et al. randomly assigned
151 patients with metastatic non–small-cell lung cancer to:
1) usual oncology care or 2) usual oncology care plus early
palliative care. Results showed that the group that received
Fig. 2 Clinical prediction of survival (CPS) versus actual survival (AS) for each individual. Each point represents a patient. Points around the 45
degree line represent patients who lived as long as predicted, points above the line represent patients who lived shorter than predicted, and
points below the line represent patients who lived longer than predicted. Pearson correlation coefficient of 0.042 (p = 0.568). Four outliers are not
shown (AS 220; 194; 192; 183 weeks versus a CPS of 20; 20; 12; 20 weeks)
Fig. 3 Overall survival function of the actual survival (AS, blue curve) versus the clinical prediction of survival (CPS, red curve) in all patients
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Table 2 Characteristics of the prediction groups
Overestimationa Correct Underestimationa P Value
No. of patients 112 (58.6%) 35 (18.3%) 44 (23.0%)
Median age, years (Q1– Q3) 65.0 (58.0–76.8) 61.0 (56.0–77.0) 64.0 (54.3–75.5) 0.627
Sex
Men 80 (71.4%) 25 (71.4%) 33 (75.0%) 0.898
Women 32 (28.6%) 10 (28.6%) 11 (25.0%)
Tumor localization
Lip 0 0 0
Oral cavity 34 (30.4%) 10 (28.6%) 10 (22.7%)
Oropharynx 28 (25.0%) 9 (25.7%) 17 (38.6%)
Nasopharynx 1 (0.9%) 2 (5.7%) 1 (2.3%)
Hypopharynx 14 (12.5%) 5 (14.3%) 7 (15.9%) –
Larynx 24 (21.5%) 4 (11.5%) 5 (11.3%)
Nasal cavity 2 (1.8%) 1 (2.9%) 0
Maxillary sinus 4 (3.6%) 1 (2.9%) 0
Salivary gland 1 (0.9%) 1 (2.9%) 0
Unknown primary 4 (3.6%) 2 (5.7%) 4 (9.1%)
Tumor stage
I-III 7 (6.3%) 2 (5.7%) 6 (13.6%)
IVa 34 (30.4%) 6 (17.1%) 15 (34.1%) –
IVb 18 (16.1%) 8 (22.9%) 5 (11.4%)
IVc 53 (47.3%) 19 (54.3%) 18 (40.9%)
ACE-27b
0 (none) 25 (22.3%) 10 (28.6%) 11 (25.0%)
1 (mild) 41 (36.6%) 6 (17.1%) 14 (31.8%) 0.409
2 (moderate) 31 (27.7%) 10 (28.6%) 12 (27.3%)
3 (severe) 15 (13.4%) 9 (25.7%) 7 (15.9%)
Marital status
Alone 46 (41.8%) 14 (42.4%) 22 (50.0%) 0.642
Married / partner 64 (58.2%) 19 (57.6%) 22 (50.0%)
Smoking
Current / past 96 (87.3%) 29 (87.9%) 37 (84.1%) 0.848
No 14 (12.7%) 4 (12.1%) 7 (15.9%)
Alcohol
Current / past 88 (80.7%) 24 (72.7%) 39 (88.6%) 0.206
No 21 (19.3%) 9 (27.3%) 5 (11.4%)
Median no. alcohol units / day (Q1 – Q3) 2.0 (0.3–6.0) 3.0 (0–5.0) 3.0 (1.0–4.0) 0.925
Median BMIc (Q1-Q3) 20.9 (17.9–23.9) 20.4 (18.4–22.8) 21.2 (18.6–24.8) 0.716
Palliative sedation 36 (32.1%) 11 (31.4%) 21 (47.7%) 0.159
Carotid blowout syndrome 7 (6.3%) 1 (2.9%) 1 (2.3%) –
Median survival, weeks (95% CI)
Actual survival 6.0 (4.8–7.2) 23.0 (19.1–6.9) 35.0 (32.1–37.9) 0.000
Clinical Prediction of Survival 20 (19.5–20.5) 20 (12.8–27.2) 20 (18.9–21.1) 0.002
aOverestimation: patients lived shorter than expected, actual survival is > 25% shorter than the clinical prediction of survival. Underestimation: patients
lived longer than expected, actual survival is > 25% longer than the clinical prediction of survival
b Adult Comorbidity Evaluation 27
c Body Mass Index
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early palliative care had significant better QoL, less
depressive symptoms and lived longer while they re-
ceived less aggressive treatment [39]. Another study
among 4493 terminal patients found that hospice care
significantly extended survival in patients with lung
and pancreatic cancer [40].
Strengths and limitations
A major strength of this study is the paucity of research
on this topic among palliative HNC patients. Further-
more, we asked physicians to give a clinical prediction at
the moment that this was highly relevant to the patient:
shortly after disclosing the palliative diagnosis. Previous
studies among other patient groups are often heteroge-
neous of design and include estimations that are given
down the road instead of at the beginning of the pallia-
tive phase. However, we also excluded 50 cases because
survival was predicted more than 3 weeks after the
outpatient visit in which the palliative diagnosis was
discussed. The reason for exclusion was to limit doctors’
recall bias. Although this 3 week cut-off point leads to
data loss, no significant differences were found between
the inclusion and exclusion group. Another limitation of
this study is the number of available variables to com-
pare the prediction groups.
Clinical implications & future research
Our results show that HNC treating physicians tend to
overestimate survival. This can result in suboptimal use
of palliative and end-of-life care. Discussing prognosis as
soon as possible in the disease trajectory, enables
patients to make well-considered end-of-life choices and
prepare for a good death. We hope that sharing these
results will make HNC treating physicians become more
aware of their tendency to overestimate survival. Future
research could aid to fill this gap by developing a prog-
nostic model that predicts survival more accurately.
Such a model could help physicians’ to disclose more ac-
curate prognostic information to guide their discussions
with patients and caregivers. Although many prognostic
models have been developed, few are actually used in
clinical practice [41, 42]. One of the key factors for suc-
cessful implementation is whether a model is supported
by professionals in the field in question [41]. Previous
research by Hallen et al. showed physicians’ willingness
to use prognostic models in end-of-life care, aiming to
improve prognostic confidence [15]. It also enabled
them to take a more directive role in specific cases
where the expected prognosis significantly differed from
patients’ expectations [15]. Also, in case of conflicting
opinions about prognosis, especially among physicians, it
was thought to be helpful and reduce ambiguity [15].
We recently updated our prognostic model “OncologIQ”
and added new prognostic factors [43, 44]. OncologIQ
has been developed to support shared decision making
(SDM) in patients with primary HNC that are eligible
for curative treatment. The model calculates the 1- to
10-year overall survival based on several prognostic fac-
tors like age, sex, comorbidity, and socioeconomic status
[45–47]. Currently, we are developing a similar prognos-
tic model for palliative HNC patients. Hopefully, this
model will take away some reluctance to discuss the
prognosis in the palliative phase, and give rise to more
realistic prognostic discussions. Due to the implementa-
tion of our Healthcare Monitor [48] we are routinely
collecting data on the QoL and functioning in the pallia-
tive phase, using the EORTC QLQ-C15-PAL [20]. These
data can be used in future prognostic research to model
QoL. Indeed information on prognosis is not a stand-
alone concept and future research should focus on how
to share this information with palliative patients’ and
their caregivers during patient-clinician discussions [49].
Conclusions
This study addresses the difficulty of providing an accur-
ate survival estimation of HNC patients in the palliative
phase. It is an important topic to study as patients in this
phase often desire accurate prognostic information. Dis-
cussing this as soon as possible in the disease trajectory,
enables patients to make well-considered end-of-life
choices and prepare for a good death. We hope that
physicians treating HNC will become more aware of
their tendency to overestimate survival, as this optimism
can result in suboptimal use of palliative and end-of-life
care. The future development of a prognostic model for
incurable HNC patients, could help physicians with per-
sonalized prognostic counseling.
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